Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

JAMA - Journal of the American Medical Association

Volumn 320, Issue 14, 2018, Pages 1455-1463

  Dellinger, R Phillip ^a   Bagshaw, Sean M ^b   Antonelli, Massimo ^c   Foster, Debra M ^d   Klein, David J ^e   Marshall, John C ^e   Palevsky, Paul M ^f   Weisberg, Lawrence S ^a   Schorr, Christa A ^a   Trzeciak, Stephen ^a   Walker, Paul M ^d  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d Spectral Diagnostics Inc   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

ADULT; AIR EMBOLISM; APACHE; ARTICLE; BIOASSAY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSESSMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOTOXIN ACTIVITY ASSAY; FEMALE; FOLLOW UP; HEMOPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN DYSFUNCTION SCORE; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TERTIARY CARE CENTER; VEIN EMBOLISM; AGED; BLOOD; CLINICAL TRIAL; HOSPITAL MORTALITY; MIDDLE AGED; SURVIVAL ANALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; ENDOTOXINS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; POLYMYXIN B; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 85054532732     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.14618     Document Type: Article

References (20)

1. Opal SM, Scannon PJ, Vincent JL, Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999; 180 (5): 1584-1589. doi: 10.1086/315093 10515819
2. Romaschin AD, Harris DM, Ribeiro MB, A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods. 1998; 212 (2): 169-185. doi: 10.1016/S0022-1759(98)00003-9 9672205
3. Klein DJ, Derzko A, Foster D, Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock. 2007; 28 (5): 524-529. 17589381
4. Angus DC, Birmingham MC, Balk RA,; E5 Study Investigators. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA. 2000; 283 (13): 1723-1730. doi: 10.1001/jama.283.13.1723 10755499
5. Dellinger RP, Tomayko JF, Angus DC,; Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med. 2009; 37 (11): 2929-2938. doi: 10.1097/CCM.0b013e3181b0266c 19770753
6. Levin M, Quint PA, Goldstein B,; rBPI21 Meningococcal Sepsis Study Group Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet. 2000; 356 (9234): 961-967. doi: 10.1016/S0140-6736(00)02712-4 11041396
7. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR; CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121 (1): 1-5. doi: 10.7326/0003-4819-121-1-199407010-00001 8198341
8. Opal SM, Laterre PF, Francois B,; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013; 309 (11): 1154-1162. doi: 10.1001/jama.2013.2194 23512062
9. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003; 7 (1): 108-114. doi: 10.1046/j.1526-0968.2003.00005.x 12921125
10. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014; 15: 218. doi: 10.1186/1745-6215-15-218 24916483
11. Marshall JC, Foster D, Vincent JL,; MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004; 190 (3): 527-534. doi: 10.1086/422254 15243928
12. Romaschin AD, Klein DJ, Marshall JC. Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care. 2012; 16 (6): 248. doi: 10.1186/cc11495 23206992
13. Dellinger RP, Levy MM, Rhodes A,; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41 (2): 580-637. doi: 10.1097/CCM.0b013e31827e83af 23353941
14. Cruz DN, Antonelli M, Fumagalli R, Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23): 2445-2452. doi: 10.1001/jama.2009.856 19531784
15. Levy MM, Rhodes A, Phillips GS, Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med. 2014; 40 (11): 1623-1633. doi: 10.1007/s00134-014-3496-0 25270221
16. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?. Crit Care Med. 2014; 42 (7): 1714-1721. doi: 10.1097/CCM.0000000000000325 24717456
17. Payen DM, Guilhot J, Launey Y,; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41 (6): 975-984. doi: 10.1007/s00134-015-3751-z 25862039
18. Novelli G, Feretti G, Ruberto F, Morabito V, Pugliese F. Early management of endotoxemia using the endotoxin activity assay and polymyxin-B based hemoperfusion: endotoxin removal in septic shock in clinical settings. In: Ronco C, Piccinni P, Rosner MH, eds. Endotoxin and Endotoxin Shock: Disease Diagnosis and Therapy. Vol 167. Basel, Switzerland: Karger; 2010: 91-101.
19. Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel Insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017; 44 (3): 193-197. doi: 10.1159/000475982 28601867
20. Pais de Barros JP, Gautier T, Sali W, Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay. J Lipid Res. 2015; 56 (7): 1363-1369. doi: 10.1194/jlr.D059725 26023073